Scott M. Rocklage, Ph.D. is a founding partner at 5AM Ventures, a venture capital firm. He initially joined as a venture partner in 2003 and then became a managing partner before his current title role at 5AM Ventures.
Founded in 2002, 5AM Ventures are particularly keen on investing in next generation life science companies. The type of companies they’re interested in deal with innovative research instruments, the discovery and development of various therapeutics, drug deliverance technologies and other medical technologies. Learn more about Scott Rocklage: https://www.twst.com/bio/scott-m-rocklage/ and https://scottrocklage.wordpress.com/
The firm has invested in more than fifty-four companies worldwide since their launch. Prior to 5Am Ventures, Dr. Rocklage used to work as the CEO and chairman for Cubist Pharmaceuticals, he was also the president and CEO of Nycomed Salutar from the years of 1992 to 1994.
Dr. Scott Rocklage graduated from the University of California, Berkeley, with a Bachelor of Science degree in Chemistry.
He received his Ph.D. in Chemistry from the Massachusetts Institute of Technology and researched and studied in the university’s famed laboratory of the 2005 Nobel Prize winner, Richard Schrock. Read more: Scott Rocklage | Ideamesch and Scott Rocklage | Crunchbase
During his time working for Nycomed Salutar, he was responsible for designing and initiating research projects that created new drugs products with human clinical trials. With over twenty years of experience in healthcare management, Dr. Rocklage has then went on to release three brand new drugs applications with the approval of the Food and Drug Administration: Omniscan, Cubicin and Teslascan.
Throughout his career, he has managed to invent an co-invent more than thirty U.S. patents and has released over a hundred peer-reviewed publications.